In the world of metabolic research, we are witnessing a rapid evolution. First came Semaglutide, the GLP-1 pioneer. Then came Tirzepatide, the dual-agonist powerhouse. Now, all eyes are on Retatrutide, the "Triple G" molecule that is pushing the boundaries of what is biologically possible in weight management.
If you are designing a research protocol, which…